Get started
Author

Héctor Perez‐Montoyo

Observed names: H. Perez-Montoyo, H. Pérez-Montoyo, H. PérezMontoyo, Hector Perez Montoyo, Hector Perez-Montoyo, Hector Perez‐Montoyo, Hector Pérez-Montoyo, Héctor Perez-Montoyo, Héctor Pérez-Montoyo, Héctor Pérez‐Montoyo, Perez-Montoyo, Héctor
ORCID: 0000-0002-9540-9604
Observed ORCID: 0000-0002-9540-9604
OpenAlex ID: A5023467490
The anti-cancer drug ABTL0812 induces ER stress-mediated cytotoxic autophagy by increasing dihydroceramide levels in cancer cells
2020 · Pau Muñoz-Guardiola, Josefina Casas, et al. · Autophagy · 121
Targeting p38α Increases DNA Damage, Chromosome Instability, and the Anti-tumoral Response to Taxanes in Breast Cancer Cells
2018 · Begoña Cánovas, Ana Igea, et al. · Cancer Cell · 107
PDF
Resistance to Taxanes in Triple-Negative Breast Cancer Associates with the Dynamics of a CD49f+ Tumor-Initiating Population
2017 · Jorge Gómez-Miragaya, Marta Palafox, et al. · Stem Cell Reports · 79
PDF
Therapeutic potential of the new TRIB3-mediated cell autophagy anticancer drug ABTL0812 in endometrial cancer
2019 · Isidre Felip, Cristian Pablo Moiola, et al. · Gynecologic Oncology · 43
The ERK5/NF-κB signaling pathway targets endometrial cancer proliferation and survival
2022 · Nora Diéguez-Martínez, Sergio Espinosa-Gil, et al. · Cellular and Molecular Life Sciences · 40
PDF
Therapeutic Potential of Autophagy Modulation in Cholangiocarcinoma
2020 · Hector Perez-Montoyo · Cells · 35
PDF
The novel proautophagy anticancer drug ABTL0812 potentiates chemotherapy in adenocarcinoma and squamous nonsmall cell lung cancer
2020 · Anna López‐Plana, Patricia Fernández‐Nogueira, et al. · International Journal of Cancer · 24
PDF
RANK is a poor prognosis marker and a therapeutic target in ER‐negative postmenopausal breast cancer
2023 · Marina Ciscar, Eva M Trinidad, et al. · EMBO Molecular Medicine · 21
PDF
The antitumour drug ABTL0812 impairs neuroblastoma growth through endoplasmic reticulum stress-mediated autophagy and apoptosis
2020 · Laia París-Coderch, Aroa Soriano, et al. · Cell Death and Disease · 20
PDF
ENDOLUNG trial. A phase 1/2 study of the Akt/mTOR inhibitor and autophagy inducer Ibrilatazar (ABTL0812) in combination with paclitaxel/carboplatin in patients with advanced/recurrent endometrial cancer
2024 · Alexandra Leary, Purificación Estévez-García, et al. · BMC Cancer · 14
Anticancer effects of ABTL0812, a clinical stage drug inducer of autophagy-mediated cancer cell death, in glioblastoma models
2022 · Andrea Mancini, Alessandro Colapietro, et al. · Frontiers in Oncology · 12
ENDOLUNG trial, part II. A phase II study of the Akt/mTOR inhibitor and autophagy inducer ibrilatazar (ABTL0812) in combination with paclitaxel/carboplatin in patients with squamous non-small cell lung cancer
2025 · Joaquim Bosch-Barrera, Purificación Estévez-García, et al. · Lung Cancer · 11
ABTL0812 enhances antitumor effect of paclitaxel and reverts chemoresistance in triple‐negative breast cancer models
2022 · Emma Polonio‐Alcalá, Sònia Solé‐Sánchez, et al. · 癌症：英文版 · 11
PDF
Assessment of biological activity in RAW 264.7 cell line stimulated with lipopolysaccharide using dynamic laser speckle
2016 · Rolando J. González-Peña, Héctor Pérez-Montoyo, et al. · Applied Physics B · 6
Correction: ENDOLUNG trial. A phase 1/2 study of the Akt/mTOR inhibitor and autophagy inducer Ibrilatazar (ABTL0812) in combination with paclitaxel/carboplatin in patients with advanced/recurrent endometrial cancer
2024 · Alexandra Leary, Purificación Estévez-García, et al. · BMC Cancer · 2
PDF
Phase 2 clinical trial of the proautophagic drug ABTL0812 combined with paclitaxel and carboplatin in first-line patients with advanced squamous non-small cell lung carcinoma.
2023 · Joaquim Bosch-Barrera, Teresa Moran, et al. · Journal of Clinical Oncology · 2
PDF
Abstract 1805: ABTL0812, a Phase 2 clinical stage pro-autophagy anticancer drug exhibits immunomodulatory effects that modify tumor microenvironment in pancreatic cancer models
2021 · Guillermo Yoldi, Pau Munoz-Guardiola, et al. · Cancer Research · 1
MA01.06 Phase 2 of Pro-Autophagic Drug ABTL0812 in Combination With First-Line Paclitaxel and Carboplatin in IIIb/IV Squamous NSCLC
2021 · J. Bosch-Barrera, T. Moran, et al. · Journal of Thoracic Oncology · 1
PDF
864P Phase II of ABTL0812, a pro-autophagic drug, in combination with paclitaxel and carboplatin (P/C) as first-line treatment in advanced/recurrent endometrial cancer
2020 · A. Leary, P. Estévez-García, et al. · Annals of Oncology · 1
Determination of recommended phase II dose of ABTL0812, a novel regulator of Akt/mTOR axis, by pharmacokinetic-pharmacodynamic modelling
2016 · J. Alfon, L. Vidal, et al. · Annals of Oncology · 1
PDF
Phase IIb randomized trial of FOLFIRINOX plus ibrilatazar (ABTL0812) versus placebo as first-line treatment in metastatic pancreatic cancer: An analysis from the PanC-ASAP study.
2026 · Davendra Sohal, Anup Kasi, et al. · Journal of Clinical Oncology
From bench to bedside: ABTL0812 and immunotherapy as a breakthrough strategy for neuroblastoma (was selected for Fire-session)
2026 · M.J. Pérez-Garcia, L. Valero, et al. · EJC Paediatric Oncology
The ER stress inducer ABTL0812/ibrilatazar potentiates standard chemotherapies and mitigates the immunosuppressive microenvironment in preclinical models of pancreatic cancer
2026 · Lorena Usero, Guillermo Yoldi, et al. · SSRN Electronic Journal
Understanding Ibrilatazar’s mechanism of action: Addressing concerns about autophagy in cancer Therapy
2025 · Joaquim Bosch-Barrera, Héctor Pérez-Montoyo, et al. · Lung Cancer
RETRACTED: Corrigendum: Anticancer effects of ABTL0812, a clinical stage drug inducer of autophagy-mediated cancer cell death, in glioblastoma models
2025 · Andrea Mancini, Alessandro Colapietro, et al. · Frontiers in Oncology
PDF
Works count: 31
Citation count: 552
H-index: 11
I10-index: 13
Year
Topic
Type